Seer, Inc. SEER
We take great care to ensure that the data presented and summarized in this overview for Seer, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SEER
View all-
Softbank Group Corp Minato Ku Tokyo, M05.14MShares$10.3 Million0.05% of portfolio
-
Sb Global Advisers LTD London, X05.14MShares$10.3 Million3.45% of portfolio
-
Siren, L.L.C. New York, NY4MShares$8 Million0.34% of portfolio
-
Black Rock Inc. New York, NY2.64MShares$5.29 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.22MShares$4.44 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.14MShares$4.29 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA1.34MShares$2.69 Million0.13% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.11MShares$2.22 Million0.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5816KShares$1.63 Million1.54% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX737KShares$1.47 Million0.04% of portfolio
Latest Institutional Activity in SEER
Top Purchases
Top Sells
About SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Transactions at SEER
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Terrance Mcguire |
BUY
Conversion of derivative security
|
Indirect |
4,088
+1.87%
|
-
|
|
Dec 09
2025
|
Omid Farokhzad CEO AND CHAIR |
BUY
Conversion of derivative security
|
Indirect |
2,117,138
+50.0%
|
-
|
|
Dec 09
2025
|
Omid Farokhzad CEO AND CHAIR |
BUY
Conversion of derivative security
|
Direct |
1,438,057
+34.95%
|
-
|
|
Nov 19
2025
|
Omid Farokhzad CEO AND CHAIR |
SELL
Open market or private sale
|
Direct |
33,838
-2.66%
|
$33,838
$1.97 P/Share
|
|
Nov 19
2025
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
6,797
-1.53%
|
$6,797
$1.97 P/Share
|
|
Sep 02
2025
|
Isaac Ro |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+50.0%
|
-
|
|
Aug 20
2025
|
Omid Farokhzad CEO AND CHAIR |
SELL
Open market or private sale
|
Direct |
33,992
-2.6%
|
$67,984
$2.04 P/Share
|
|
Aug 20
2025
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
6,827
-1.54%
|
$13,654
$2.04 P/Share
|
|
Jul 07
2025
|
Nicolas H Phd Roelofs |
BUY
Grant, award, or other acquisition
|
Direct |
17,083
+18.55%
|
-
|
|
Jul 07
2025
|
Robert Langer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+2.48%
|
-
|
|
Jul 07
2025
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+15.46%
|
-
|
|
Jul 07
2025
|
Dipchand Nishar |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+22.73%
|
-
|
|
Jul 07
2025
|
Meeta Gulyani |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+16.01%
|
-
|
|
Jun 13
2025
|
Dipchand Nishar |
SELL
Open market or private sale
|
Direct |
30,253
-38.07%
|
$60,506
$2.08 P/Share
|
|
May 20
2025
|
Omid Farokhzad CEO AND CHAIR |
SELL
Open market or private sale
|
Direct |
33,663
-2.51%
|
$67,326
$2.08 P/Share
|
|
May 20
2025
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
6,760
-1.5%
|
$13,520
$2.08 P/Share
|
|
Feb 18
2025
|
Omid Farokhzad CEO AND CHAIR |
SELL
Payment of exercise price or tax liability
|
Direct |
88,494
-6.2%
|
$176,988
$2.3 P/Share
|
|
Feb 18
2025
|
David R. Horn PRESIDENT & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
26,572
-5.57%
|
$53,144
$2.3 P/Share
|
|
Feb 04
2025
|
Omid Farokhzad CEO AND CHAIR |
SELL
Open market or private sale
|
Direct |
8,068
-0.56%
|
$16,136
$2.24 P/Share
|
|
Feb 04
2025
|
David R. Horn PRESIDENT & CFO |
SELL
Open market or private sale
|
Direct |
3,550
-0.74%
|
$7,100
$2.24 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 140K shares |
|---|---|
| Conversion of derivative security | 3.56M shares |
| Payment of exercise price or tax liability | 115K shares |
|---|---|
| Open market or private sale | 164K shares |